Tvardi Therapeutics (LTS:0HTC) Beginning Cash Position : £29.34 Mil (As of Mar. 2025)

View and export this data going back to 2025. Start your Free Trial

What is Tvardi Therapeutics Beginning Cash Position?

Tvardi Therapeutics's Beginning Cash Position for the quarter that ended in Mar. 2025 was £29.34 Mil.

Tvardi Therapeutics's quarterly Beginning Cash Position declined from Mar. 2024 (£42.25 Mil) to Sep. 2024 (£0.00 Mil) but then increased from Sep. 2024 (£0.00 Mil) to Mar. 2025 (£29.34 Mil).

Tvardi Therapeutics's annual Beginning Cash Position increased from . 20 (£0.00 Mil) to Dec. 2022 (£50.37 Mil) but then declined from Dec. 2022 (£50.37 Mil) to Dec. 2023 (£16.98 Mil).

Tvardi Therapeutics Beginning Cash Position Historical Data

The historical data trend for Tvardi Therapeutics's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tvardi Therapeutics Beginning Cash Position Chart

Tvardi Therapeutics Annual Data

Trend

Dec22

Dec23

Beginning Cash Position

50.37

16.98

Tvardi Therapeutics Quarterly Data
	Dec22	Dec23	Mar24	Sep24	Mar25
Beginning Cash Position	-	22.65	42.25	-	29.34

Tvardi Therapeutics Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.

Tvardi Therapeutics Beginning Cash Position Related Terms

Thank you for viewing the detailed overview of Tvardi Therapeutics's Beginning Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

Tvardi Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tvardi Therapeutics Inc (LTS:0HTC) » Definitions » Beginning Cash Position

Comparable Companies

Traded in Other Exchanges

TVRD:USA 69C:Germany

Address

3 Sugar Creek Center boulevard, Suite 525, Sugar Land, TX, USA, 77478

Website

Tvardi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases. Its key product candidate, TTI-101, is in Phase 2 clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC). Its second product candidate, TTI-109, is structurally related to, yet chemically distinct from, TTI-101 and is designed to enhance the ability to target STAT3.

Tvardi Therapeutics Headlines

No Headlines